成都明晟持有近两千万股 每经记者｜鄢银婵 每经编辑｜魏官红 2026年1月8日，深圳市精锋医疗科技股份有限公司（以下简称精锋医疗，证券简称精锋医疗-B，HK02675，股价58.050港元，市值 225.070亿港元）正式登陆港交所主板。上市首日，公司股价涨超30%，盘中最高达60.000港元/股，截至当日收盘，精锋医疗股价为 56.600港元/股。 每经媒资库图 《每日经济新闻》记者注意到，这家由"85后"博士夫妇创办的企业，在成立不足9年的时间里，完成了从10万元启动资金到估值超百亿 元的跨越，其有3款产品已经获批，核心产品多孔腔镜手术机器人已在国内获批，用于泌尿外科、妇科、普外科及胸外科手术，累计签 约销量达61台，覆盖全球20余个国家。 不过，作为产品商业化起步不久的公司，精锋医疗同样面临常年亏损、市场竞争愈发激烈的问题。一方面，核心产品赛道已有10余款 产品厮杀；另一方面，面对已实现国产化的达芬奇系统，其"价格优势"不及从前。 1月12日，精锋医疗股价上涨3.66%。 2017年5月4日，王建辰和高元倩夫妇在深圳认缴出资10万元，注册成立了精锋医疗。 这对创始人还是大学同学，两人分别在2013年和2 ...

消息面上，微创机器人公司近日宣布，依托其自主研发的"神经元MicroGenius"多模态自主手术大模 型，已成功完成全球首例"大模型自主手术"在体动物实验。这一成果在既有公开文献与医疗实践中尚无 先例，故本次实验是全球范围内首次由多模态自主手术大模型驱动手术机器人，在活体动物体内场景中 以流程级自主方式完成关键手术步骤。 值得注意的是，公司此前公告，综合订单方面，经本集团内部初步统计，本集团旗下腔镜、骨科、血管 介入核心产品的综合订单量累计突破230台。其中，核心产品图迈腔镜手术机器人(图迈)于全球范围内 累计商业化订单超过160台，含今年新获订单近120台。根据公开统计数据，图迈2025年全球订单量已跻 身全球前二。 智通财经APP获悉，微创机器人-B(02252)早盘涨超7%，截至发稿，涨5.7%，报26.7港元，成交额1.15亿 港元。 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C 智谱 港股｜挂牌上市 据IPO早知道消息，北京智谱华章科技股份有限公司（以下简称"智谱"）于2026年1月8日正式以"2513"为股票代码在港交所主板 挂牌上市，成为"全球大模型第一股"。 智谱计划在本次IPO中发行37,419,500股H股。其中香港公开发售获1,159.46倍认购，国际发售获15.28倍认购。同时，智谱还在本 次IPO发行中引入了一个颇为多元化的基石投资阵容，涵盖北京核心国资、头部保险资金、大型公募基金、明星私募基金、产业 投资方等。以每股116.2港元的发行价计算，智谱本次IPO募资总额超43亿港元。 自2019年成立伊始，智谱就瞄向AGI，原创性提出基于自回归填空的通用预训练范式GLM（General Language Model）并研发出 中国首个预训练大模型框架。而后，智谱又陆续推出中国首个百亿模型、首个开源千亿模型、首个对话模型、首个多模态模型 和全球首个设备操控智能体，打造了世界范围内最为先进而全面的模型组合及智能体（AI Agent）产品，是国内罕有在原创技术 路线上与全球顶尖水平保持同步的厂商，故被誉 ...

马斯克预测通用人工智能将在2026年到来，并称机器人将在4至5年内全面超越人类外科医生，引发医疗行业震动。 近日，科技富豪、特斯拉CEO马斯克在一次长达三小时到访谈中再爆惊人之语。他的一段话直指外科医生的"饭碗"。马斯克称，通用人工智能（AGI）在 2026年就将到来，3年内，机器人在手术技能上将超越人类；4年后，将达到"完胜任何人类医生"的水平。 马斯克正专注于研发人形机器人擎天柱（Optimus）。他认为，技术已经进化到一个奇点。在通用人工智能的引领下，擎天柱人形机器人对医生的冲击是 巨大的，外科医生可能要彻底失业了。 "4年后，机器人将超越任何人类外科医生，5年后它将完全碾压人类外科医生，包括顶级外科医生。每个人都将获得比现任总统现在所享受的医疗服务还 要好，学医将毫无意义。"马斯克在访谈中放出豪言。 但在专业医生看来，要在5年之内实现"机器人自己看片子、拿起手术刀切除肿瘤，全程无须人类医生插手"的愿景根本不可能，至少还要经历几代人的努 力。 也有投资人表示，"马斯克式的时间表"习惯将目标设定在物理极限的边缘，用激进的承诺来倒逼技术进步，同时吸引资本和顶级人才的关注。 午休时间就能干一台脑部手术? 这番 ...

Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) successfully listed on the Hong Kong Stock Exchange on January 8, with an opening increase of 36.45%, reaching HKD 59.00 per share, and a market capitalization of HKD 22.876 billion [1][4]. Company Overview - Precision Medical's IPO was priced at HKD 43.24 per share, with a total issuance of 27.7222 million shares, raising a net amount of HKD 1.117 billion [4]. - The company has received approval for three surgical robot products, including the MP1000 and SP1000, which are already in clinical use across various surgical fields [5][6]. Investment and Market Position - The investor lineup for Precision Medical includes prominent firms such as Sequoia China, Temasek, and UBS AM Singapore, with total subscriptions amounting to USD 75 million [5]. - The company has completed over 12,000 robot-assisted surgeries using the MP1000 and over 2,000 using the SP1000 prior to the IPO [8]. Industry Context - The surgical robot market in China is projected to grow from RMB 2.714 billion in 2019 to RMB 7.184 billion by 2024, with a compound annual growth rate (CAGR) of 21.5% [11]. - The market is competitive, with major players like Intuitive Surgical's da Vinci system holding over 60% of the high-end market share, while domestic companies like MicroPort and Tianzhihang are also emerging [11]. Financial Performance - Precision Medical reported revenues of RMB 48.042 million, RMB 160 million, and RMB 149 million for 2023, 2024, and the first half of 2025, respectively, with corresponding losses of RMB 213 million, RMB 219 million, and RMB 89.087 million [12]. - The company has maintained high R&D expenditures, amounting to RMB 171 million, RMB 226 million, and RMB 97 million during the same periods, which supports product innovation but increases short-term profitability pressure [12].

Core Insights - The article highlights the emergence of Shenzhen-based Jingfeng Medical as a key player in the global surgical robot market, leveraging over 600 patents to reshape the competitive landscape dominated by foreign brands [1][2]. Company Overview - Jingfeng Medical, established in 2017, focuses on the design, research, and manufacturing of surgical robots, with a product matrix that includes multi-port and single-port laparoscopic surgical robots, as well as natural orifice surgical robots [2]. - The company is the first in China and the second globally to obtain regulatory approval for all three types of surgical robots, positioning its technology among the world's top tier [2]. Market Trends - The penetration rate of robotic-assisted laparoscopic surgery in China is currently low at 0.7% in 2024, with expectations to rise to 3.0% by 2033, compared to 21.9% in the U.S. in 2024, indicating significant growth potential for domestic companies like Jingfeng Medical [3]. Commercialization and Financial Performance - Jingfeng Medical began commercializing its multi-port laparoscopic surgical robot in December 2022, achieving a leading position in the domestic market with 20 units sold in 2024 [4]. - The company reported revenues of 48.04 million yuan in 2023, projected to increase to 160 million yuan in 2024, with a 400% year-on-year growth in the first half of 2025 [4][5]. - The revenue structure shows that 92.9% comes from surgical robot sales, with significant contributions from overseas markets, indicating successful global expansion [5]. Investment and Funding - Jingfeng Medical has raised over 2 billion yuan through six rounds of financing, attracting investments from notable institutions such as Sequoia China and Temasek [6]. - The recent IPO attracted a strong base of cornerstone investors, reflecting high market confidence in the company's technological capabilities and growth potential [6]. Competitive Landscape - The company has established a formidable competitive barrier with its complete product matrix of multi-port, single-port, and natural orifice surgical robots, being the only company in China and one of two globally to have all these products approved [8]. - The potential for high returns is emphasized, with expectations of continued growth driven by increased penetration of robotic-assisted surgeries and expansion into international markets [8].

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as "Precision Medical") is the first company in China and the second globally to commercialize both multi-port and single-port surgical robots, officially listing on the Hong Kong Stock Exchange on January 8, 2026 [1] Group 1: IPO and Financial Performance - Precision Medical issued a total of 27,722,200 H-shares in its IPO, with a subscription rate of 1,091.94 times for the Hong Kong public offering and 25.18 times for the international offering [3] - The company raised approximately HKD 1.199 billion at an issue price of HKD 43.24 per share, with an opening price of HKD 59, resulting in a market capitalization exceeding HKD 22.8 billion [3] - In the first half of 2025, Precision Medical achieved revenue of approximately RMB 149 million, representing a nearly 400% year-on-year growth, with a gross margin of about 62.8% [3] Group 2: Future Plans and Innovations - Precision Medical aims to leverage its IPO as a new starting point to increase investment in cutting-edge technologies, complex surgical procedures, and remote surgery, while steadily advancing capacity building and global market expansion [3] - The company is committed to providing safer, more efficient, and affordable minimally invasive surgical solutions, contributing to the high-quality development of China's high-end medical equipment industry [4] Group 3: Company Background and Technology - Founded in May 2017, Precision Medical is a strategic investment enterprise of the National Social Security Fund and a key player in the field of domestically developed surgical robots in China [6] - The company has developed a comprehensive product portfolio, including multi-port and single-port surgical robots, bronchoscopic surgical robots, and traditional minimally invasive surgical instruments, supported by a robust R&D team and a strong intellectual property foundation with 734 patents [6] - Precision Medical has established a "three-in-one" surgical solution combining multi-port, single-port, and remote systems, promoting advancements in surgical techniques and sharing high-quality medical resources globally [6]

Core Viewpoint - The debut of Precision Medical-B (2675.HK) on the Hong Kong Stock Exchange was highly successful, with shares initially rising over 38% to reach HKD 60, resulting in a market capitalization of HKD 23.2 billion [1] Group 1: IPO Performance - Precision Medical's IPO price was set at HKD 43.24 per share, raising a net amount of HKD 1.117 billion [2] - The public offering was oversubscribed by 1,091.94 times, while the international offering saw a 25.18 times subscription [1] Group 2: Company Overview - Precision Medical is a leading company in the surgical robotics sector, focusing on the design, development, and manufacturing of surgical robots [1] - The company has three products at different stages of research and development, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for non-invasive procedures [1] Group 3: Investor Confidence - The cornerstone investors for Precision Medical's IPO include prestigious institutions such as the Abu Dhabi Investment Authority, UBS Asset Management, Obor Capital, and Tencent, collectively contributing USD 75 million [1]

精锋医疗-B(02675)首挂上市，公告显示，每股定价43.24港元，共发行2772.22万股股份，每手100股， 所得款项净额11.17亿港元。截至发稿，涨36.45%，报59港元，成交额1.88亿港元。 方正证券认为，精锋医疗全球招股引入多元、全球化重磅基石投资人参与认购，再度掀起腔镜机器人赛 道资本关注热度。我国腔镜手术机器人行业目前手术渗透率仍不足1%、远低于美国的21.9%，市场超 40%份额也仍由达芬奇主导，国产化率提升空间仍较广阔，在国家政策端的持续支持、配置证加速放开 环境下，资本市场对该赛道的关注热度持续高涨。 公开资料显示，精锋医疗是国内医疗器械行业的先进手术机器人公司，专注于手术机器人的设计、开发 及制造。根据弗若斯特沙利文的资料，精锋医疗是中国首家、全球第二家同时取得多孔腔镜手术机器 人、单孔腔镜手术机器人及自然腔道手术机器人注册审批的企业。财务方面，2023年、2024年以及2025 年上半年，公司收入分别为4804万元、1.6亿元和1.5亿元；年内亏损分别约为2.13亿元、2.19亿元、和 8908.7万元。 ...